Article
PDT trials aim to extend knowledge from TAP, VIP studies
Baltimore-Ocular photodynamic therapy (PDT) using verteporfin (Visudyne, Novartis) already has been shown to be beneficial in the treatment of predominantly classic subfoveal choroidal neovascularization (CNV) in age-related macular degeneration (AMD).
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
